VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conferenc...
September 15 2020 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT) will present today a corporate
overview, including an update on the OVAL pivotal study, at the H.
C. Wainwright 22nd Annual Global Investment Conference being held
virtually on September 14-16, 2020.
"Our OVAL trial of VB-111 in ovarian cancer continues to
progress well, with over a third of the study participants already
enrolled," said Dror Harats, MD, Chief Executive Officer of VBL
Therapeutics. "We are pleased that the high response rate seen in
our interim analysis in March, continues to be high in the total
patient population to date. With blinded data becoming more mature,
we currently see a good correlation between the CA-125 and RECIST
responses, as well as with preliminary PFS and OS data. So far,
OVAL blinded data recapitulate what we have seen in our positive
Phase 2 study, which is very encouraging."
Presentation Details:
Date: |
Today,
Tuesday, September 15 |
Time: |
14:30 EDT |
Webcast: |
Link |
About VBLVascular Biogenics Ltd., operating
as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
being developed to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every 6-8 weeks.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated activity signals in a VBL-sponsored “all
comers” Phase 1 trial as well as in three VBL-sponsored
tumor-specific Phase 2 studies. Ofranergene obadenovec is currently
being studied in a VBL-sponsored Phase 3 potential registration
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including VB-111, including their clinical development,
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, the risk that historical clinical trial results may not
be predictive of future trial results, the impact of the COVID-19
pandemic on our business, operations, clinical trials, supply
chain, strategy, goals and anticipated timelines and clinical
results, that our financial resources do not last for as long as
anticipated, and that we may not realize the expected benefits of
our intellectual property protection. A further list and
description of these risks, uncertainties and other risks can be
found in our regulatory filings with the U.S. Securities and
Exchange Commission, including in our annual report on Form 20-F
for the year ended December 31, 2019, and subsequent filings
with the SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024